Optimalisatie van de werkingsprocessen van het Bijzonder ... - KCE

More documents

Recommendations

Info

4 Special Solidarity Fund KCE Reports 133 9.12.9 Knowledge and appreciation of the SSF criteria .................................................................... 178 9.12.10 The internal procedure within the hospital ...................................................................... 182 9.13 RESULTS FOR THE INTERVIEWS WITH PHARMA.BE AND REPRESENTATIVES OF FOUR PHARMACEUTICAL COMPANIES ...................................................................................................... 184 9.13.1 General remarks Pharma.be ...................................................................................................... 184 9.13.2 Suggestions of the pharmaceutical companies ....................................................................... 185 9.13.3 The view of the pharmaceutical companies on the SSF ....................................................... 185 9.14 INTERNATIONAL COMPARISON: FRANCE .................................................................................. 187 9.14.1 Sources ........................................................................................................................................... 187 9.14.2 Short introduction to the French healthcare system ........................................................... 187 9.14.3 The organization of healthcare provision................................................................................ 189 9.14.4 List of Chronic Diseases (Affection de Longue Durée - ALD 30) ..................................... 190 9.15 INTERNATIONAL COMPARISON: THE NETHERLANDS .......................................................... 191 9.15.1 Sources ........................................................................................................................................... 191 9.15.2 An introduction to the Dutch healthcare system ................................................................. 192 9.16 INTERNATIONAL COMPARISON: SPAIN ....................................................................................... 195 9.16.1 Sources ........................................................................................................................................... 195 9.16.2 Introduction to the Spanish healthcare system ..................................................................... 196 9.17 SSF CASES FOR INTERNATIONAL BENCHMARKING ................................................................ 202 9.17.1 The Netherlands ........................................................................................................................... 202 9.17.2 France ............................................................................................................................................. 204 9.17.3 Spain ................................................................................................................................................ 207 10 REFERENCES ............................................................................................................... 208
KCE Reports 133 Special Solidarity Fund 5 LIST OF ABBREVIATIONS AEMPS Agencia Espanola de Medicamentos y Productos Sanitario AFSSAPS Agence Française de Sécurité Sanitaire des Produits de Santé AIDS Acquired Immuno Deficiency Syndrome ALD Affectation de longue durée AME L'aide Medicale d'Etat ATU Authorisation for temporary usage ASMR L' amélioration du Service Médical Rendu/improvement in clinical value AWBZ Algemene wet bijzondere ziektekosten BBC Special Assistance Committee BOKS Belgian patient organisation for children and adults with metabolic disorders CANAM La caisse nationale d'assurance maladie des professions indépendants CE European Conformity CEPS Comité economique des Produits de Santé/French Health Care Products Economic Committee CIP Club Inter Pharmaceutique CMU Couverture maladie universelle CPA Dutch Committee for Pharmaceutical Aid CSUR Centros Servicios o Unidades de Referencia (Spanish reference centers) College Toezicht Zorgverzekeringen/Dutch supervisory board for CTZ Health insurance CVZ College van zorgverzekeraars/College of Health insurers DEBRA Dystrophic Epidermolysis Bullosa Research Organisation DRG Diseases Related Groups DRC Drug Reimbursement Commission DTC Diagnosis and treatment Combinations EB Epidermolysis Bullosa
Page 1 and 2: Optimalisatie van de werkingsproces
Page 3 and 4: Optimalisatie van de werkingsproces
Page 5 and 6: KCE reports 133A Bijzonder Solidari
Page 17: KCE reports 133A Bijzonder Solidari
Page 20 and 21: 2 Special Solidarity Fund KCE Repor
Page 28 and 29: 10 Special Solidarity Fund KCE Repo
Page 72 and 73:
54 Special Solidarity Fund KCE Repo
Page 74 and 75:
Page 76 and 77:
Page 78 and 79:
Page 80 and 81:
Page 82 and 83:
Page 84 and 85:
Page 86 and 87:
Page 88 and 89:
Page 90 and 91:
Page 92 and 93:
Page 94 and 95:
Page 96 and 97:
Page 98 and 99:
Page 100 and 101:
Page 102 and 103:
Page 104 and 105:
Page 106 and 107:
Page 108 and 109:
Page 110 and 111:
Page 112 and 113:
Page 114 and 115:
Page 116 and 117:
Page 118 and 119:
100 Special Solidarity Fund KCE Rep
Page 120 and 121:
Page 122 and 123:
Page 124 and 125:
Page 126 and 127:
Page 128 and 129:
Page 130 and 131:
Page 132 and 133:
Page 134 and 135:
Page 136 and 137:
Page 138 and 139:
Page 140 and 141:
Page 142 and 143:
Page 144 and 145:
Page 146 and 147:
Page 148 and 149:
Page 150 and 151:
Page 152 and 153:
Page 154 and 155:
Page 156 and 157:
Page 158 and 159:
Page 160 and 161:
Page 162 and 163:
Page 164 and 165:
Page 166 and 167:
Page 168 and 169:
Page 170 and 171:
Page 172 and 173:
Page 174 and 175:
Page 176 and 177:
Page 178 and 179:
Page 180 and 181:
Page 182 and 183:
Page 184 and 185:
Page 186 and 187:
Page 188 and 189:
Page 190 and 191:
Page 192 and 193:
Page 194 and 195:
Page 196 and 197:
Page 198 and 199:
Page 200 and 201:
Page 202 and 203:
Page 204 and 205:
Page 206 and 207:
Page 208 and 209:
Page 210 and 211:
Page 212 and 213:
Page 214 and 215:
Page 216 and 217:
Page 218 and 219:
Page 220 and 221:
Page 222 and 223:
Page 224 and 225:
Page 226 and 227:
Page 228 and 229:
Page 230 and 231:
Wettelijk depot : D/2010/10.273/44
Page 232 and 233:
37. HTA Magnetische Resonantie Beel
Page 234:
108. Tiotropium in de behandeling v
show all

Optimalisatie van de werkingsprocessen van het Bijzonder ... - KCE

Create successful ePaper yourself

Delete template?

Save as template?